LupuzorTM may become the first specific and non-immunosuppressant therapy for lupus, a disabling autoimmune disease that is currently incurable.
Discovered by Sylviane Muller’s team in the CNRS Immunopathologie et Chimie Thérapeutique laboratory, in Strasbourg, this peptide is the subject of a CNRS patent (granted in 2009) and has already successfully completed phases I and II of its regulatory clinical trials, supervised by ImmuPharma-France. An international phase III pivotal trial1, also managed by this company, will begin in a few days’ time in the US when the first patient starts the treatment, before the trial is extended to Europe. Phase III is the last stage in the testing of a candidate drug, before it can be given market approval. The launch of phase III was the subject of a meeting involving around a hundred physicians on December 11-12, in Paris.
Lupus2 is a chronic autoimmune disease that affects more than five million people worldwide (around 30,000 in France), 90% of whom are women. It is characterized by the production of autoantibodies that attack different organs (skin, joints, vascular system, brain, kidneys) and cause inflammation, hence the broad range of possible symptoms: skin lesions, joint pain, thromboses, psychotic episodes, etc. To alleviate this disease with many causes, only palliative treatments are available at present, most of which are non-specific: corticosteroids and immunosuppressants, but they also weaken the immune system. Although they can stop autoimmune attacks, they also render patients highly susceptible to multiple infections. It was therefore urgent to develop a more targeted therapy.
The team led by Sylviane Muller, who received the 2015 CNRS Medal of Innovation3, developed a family of peptides (protein fragments) that can specifically correct dysfunction of the immune system4. One of these peptides, called P1405, proved capable of delaying the development of lupus in affected mice, while preserving their immune systems’ ability to fight infective agents. Since then, phase I and II clinical trials have been carried out6 by the company ImmuPharma-France, which holds an exclusive license for the patents that protect this family of peptides, all owned by the CNRS or filed as joint property. During phase II trials, the disease regressed in 62% of patients after 3 months of treatment: this is the best result ever to have been achieved for this pathology.
Following these successes, ImmuPharma-France launched its pivotal phase III trial. In the same way as during the phase IIb trials, the candidate drug will be administered under double-blind conditions once a month by the subcutaneous route, at a rate of 200 µg per injection, but the duration of treatment will be extended to a year, as opposed to 3 months previously. Two hundred patients will be included in this trial, spread across 45 centers (10 in the US and 35 in Europe7). The first patients will be recruited in the US by the end of 2015. In Europe, the trial should be starting in mid-January in the first centers, which include those in France. Recruitment should be completed by mid-2016 and the final results are anticipated at the end of 2017.
The first Investigators’ Meeting for the phase III trial took place on December 11 and 12 in Paris, and involved around a hundred American and European physicians.
Once this final phase of clinical trials is completed, and provided the results confirm those of phase IIb, LupuzorTM could be put on the market and subsequently play a central role in the treatment of patients with lupus.
According to preclinical findings, LupuzorTM may also be effective in other chronic autoimmune pathologies, such as Sjögren’s syndrome (dry eye syndrome) or Crohn’s disease (an autoimmune disease that causes chronic intestinal inflammation). Fundamental studies on these promising leads are now underway in Sylviane Muller’s laboratory.
Read more: Treatment of lupus : LupuzorTM enters phase III
The Latest on: Lupus
[google_news title=”” keyword=”Lupus” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Lupus
- Crowning Lupus awareness walk Saturday, May 4thon April 30, 2024 at 1:35 pm
AUGUSTA, Ga. (WJBF) –One step at a time. That’s how Crowning Lupus is leading the way in lupus awareness through its participation in the annual South Carolina Lupus Walk. The mission of Crowning ...
- Nursing couple in need of financial help as daughter fights for her life in lupus battleon April 29, 2024 at 8:28 pm
Ryan and Wendy Sansom who are nurses themselves in the community are in the hospital caring for their daughter Angelina Xiong who is fighting for her life in the ICY at UAB in Birmingham battling ...
- Differences in Disease Activity by Onset-Age in People with Systemic Lupus Erythematosuson April 28, 2024 at 5:00 pm
In a new study, people with systemic lupus erythematosus (SLE) who developed the disease later in life exhibited notable clinical differences and lower disease activity, however they also have the ...
- Lupus forces singer Toni Braxton into LA hospitalon April 27, 2024 at 9:34 am
Singer Toni Braxton has been hospitalized in Los Angeles. The R&B performer says in a Tweet on Friday that she's been hospitalized because of "minor health issues" related to Lupus. A spokeswoman ...
- Nick Cannon says he is a lupus warrior as he undergoes blood treatment after decade of battle with conditionon April 26, 2024 at 2:53 pm
Since 2012, actor Nick Cannon, has openly shared his struggle with lupus to support others facing the disease.
- What to Eat When You Have Lupus, According to MDs and RDson April 25, 2024 at 8:30 pm
When it comes to managing lupus symptoms, there's no set lupus diet. Here, a rheumatologist and two dietitians share which foods to generally eat or avoid.
- Why lupus can be especially tough on children; signs to look out foron April 25, 2024 at 3:50 pm
In today's Healthcast, we take a look at lupus and why this auto-immune disease can be especially tough on children.
- Nick Cannon Calls Himself a 'Lupus Warrior' While Getting Blood Work: 'Health Is the Real Wealth'on April 24, 2024 at 1:34 pm
Nick Cannon was diagnosed with lupus in January 2012 and has used his platform to share his journey, telling his followers that “health is the real wealth” ...
- Toni Braxton Was Told To Hide Her Lupus Diagnosison April 21, 2024 at 6:00 am
After her diagnosis in 2008, her management team told her to keep it private because "'People get scared around sick celebrities.'" ...
- Toni Braxton Discloses Being Advised to Conceal Lupus Diagnosis | Videoon April 18, 2024 at 5:00 pm
Toni Braxton has revealed that her management advised to conceal her 2008 diagnosis of autoimmune disorder lupus.
via Bing News